| P50 | author | Katie J Suda | Q117242955 |
| | Glen T Schumock | Q121141922 |
| P2093 | author name string | Linda M Matusiak | |
| | Robert J Hunkler | |
| | Drew J Halbur | |
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | Telaprevir for previously treated chronic HCV infection | Q34109057 |
| | National trends in prescription drug expenditures and projections for 2015. | Q34471640 |
| | The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection | Q35572125 |
| | Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States | Q35619161 |
| | Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 | Q36035889 |
| | National trends in prescription drug expenditures and projections for 2016. | Q38408006 |
| | National trends in prescription drug expenditures and projections for 2014. | Q39240419 |
| | Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013. | Q39458283 |
| | Projecting future drug expenditures--2012. | Q39650889 |
| | Projecting future drug expenditures: 2011. | Q39753424 |
| | Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States | Q40786866 |
| | Cost-effectiveness of novel regimens for the treatment of hepatitis C virus | Q41211125 |
| | Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection | Q41522918 |
| | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study | Q42202756 |
| | New Expensive Treatments for Hepatitis C Infection | Q57255675 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 65-70 | |
| P577 | publication date | 2016-11-09 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Spending on Hepatitis C Antivirals in the United States, 2009-2015. | |
| P478 | volume | 37 | |